31 May 2016 - The EMA has published an EPAR for albutrepenonacog alfa (Idelvion).

The European Commission approved Idevion on 11 May 2016 for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Idevion will be subjected to additional monitoring by the EMA.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003955/human_med_001974.jsp&mid=WC0b01ac058001d124